Erratum: Macrophages in malignant pleural effusions-alternatively activated tumor associated macrophages (Wspolczesna Onkol (2012) 16:4 (279-28) DOI: 10.5114/wo.2012.30054);Macrophages in malignant pleural effusions - Alternatively activated tumor associated macrophages

Wspolczesna Onkologia

Volumn 16, Issue 4, 2012, Pages 279-284

  Kaczmarek, Mariusz ^a   Sikora, Jan ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

M1 M2; Malignant pleural effusion; Pleural macrophages; TAM; Tumor associated macrophages

Indexed keywords

ARGINASE 1; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR8; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; SPHINGOSINE KINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

CARCINOGENESIS; CELL INFILTRATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT PLEURAL EFFUSION; PHAGOCYTOSIS; PLEURA EFFUSION; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84867683572     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2016.60412     Document Type: Erratum

References (77)

1. Gordon S. The role of the macrophage in immune regulation. Res Immunol 1998; 149: 685-688. (Pubitemid 29487163)
2. Lehnert BE. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ Health Perspect 1992; 97: 17-46.
3. Gjomarkaj M, Pace E, Melis M, Spatafora M, Profita M, Vignola AM, Bonsignore G, Toews GB. Phenotypic and functional characterization of normal rat pleural macrophages in comparison with autologous peritoneal and alveolar macrophages. Am J Respir Cell Mol Biol 1999; 20: 135-42. (Pubitemid 129504852)
4. Frankenberger M, Passlick B, Hofer T, Siebeck M, Maier KL, Ziegler-Heitbrock LH. Immunologic characterization of normal human pleural macrophages. Am J Respir Cell Mol Biol 2000; 23: 419-26.
5. Wu HM, Jin M, Marsh CB. Toward functional proteomics of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2005; 288: L585-95. (Pubitemid 40404123)
6. Adamson IY, Bowden DH. Chemotactic and mitogenic components of the alveolar macrophage response to particles ad neutrophil chemoattractant. Am J Pathol 1982; 109: 71-7. (Pubitemid 12002999)
7. Murai N, Nagai K, Fujisawa H, Hatanaka K, Kawamura M, Harada Y. Concurrent evolution and resolution in an acute inflammatory model of rat carrageenin-induced pleurisy. J Leukoc Biol 2003; 73: 456-63. (Pubitemid 38040091)
8. Cailhier JF, Sawatzky DA, Kipari T, et al. Resident pleural macrophages are key orchestrators of neutrophil recruitment in pleural inflammation. Am J Respir Crit Care Med 2006; 173: 540-7.
9. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13: 453-61. (Pubitemid 351599757)
10. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35. (Pubitemid 37328697)
11. Biswas A, Banerjee P, Mukherjee G, Biswas T. Porin of Shigella dysenteriae activates mouse peritoneal macrophage through Toll-like receptors 2 and 6 to induce polarized type I response. Mol Immunol 2007; 44: 812-20. (Pubitemid 44429977)
12. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-12. (Pubitemid 36158295)
13. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998; 161: 1983-8. (Pubitemid 28387623)
14. Mukhopadhyay S, Chen Y, Sankala M, Peiser L, Pikkarainen T, Kraal G, Tryggvason K, Gordon S. MARCO, an innate activation marker of macrophages, is a class A scavenger receptor for Neisseria meningitidis. Eur J Immunol 2006; 36: 940-9.
15. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86. (Pubitemid 39457982)
16. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303-11. (Pubitemid 44715100)
17. Patarroyo M. Adhesion molecules mediating recruitment of monocytes to inflamed tissue. Immunobiology 1994; 191: 474-7. (Pubitemid 24331473)
18. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/ arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998; 160: 5347-54. (Pubitemid 28267823)
19. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64. (Pubitemid 41746764)
20. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901-44. (Pubitemid 40563189)
21. Kaczmarek M, Nowicka A, Kozłowska M, Zurawski J, Batura-Gabryel H, Sikora J. Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions. Tumour Biol 2011; 32: 1123-32.
22. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65. (Pubitemid 34189413)
23. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166: 6483-90. (Pubitemid 32467185)
24. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995; 95: 2391-6.
25. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003; 63: 7451-61. (Pubitemid 37413488)
26. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-40.
27. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-27.
28. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011-7.
29. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005; 23: 953-64. (Pubitemid 46202315)
30. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21. (Pubitemid 30626905)
31. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and pro gnosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625-29. (Pubitemid 26338061)
32. Ohno S, Ohno Y, Suzuki N, et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004; 24: 3335-42. (Pubitemid 39390949)
33. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62: 5069-75. (Pubitemid 34984436)
34. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 177-89.
35. te Velde AA, Figdor CG. Monocyte mediated cytotoxic activity against melanoma. Melanoma Res 1992; 1: 303-9.
36. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002; 44: 143-61. (Pubitemid 36159043)
37. Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003; 23: 5015-22. (Pubitemid 38182119)
38. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10: 309-13.
39. Piras F, Colombari R, Minerba L, et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005; 104: 1246-54. (Pubitemid 41278960)
40. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001; 193: F23-26. (Pubitemid 32524459)
41. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-74. (Pubitemid 39237489)
42. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999; 57: 138-42. (Pubitemid 29385492)
43. Hamada I, Kato M, Yamasaki T, Iwabuchi K, Watanabe T, Yamada T, Itoyama S, Ito H, Okada K. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002; 22: 4281-4. (Pubitemid 36134473)
44. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000; 7: 263-9. (Pubitemid 30440592)
45. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005; 14: 425-31.
46. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000; 17: 445-51.
47. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42: 1414-21. (Pubitemid 32520728)
48. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-74. (Pubitemid 41291735)
49. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor- 1/epidermal growth factor paracrine loop. Cancer Res 2005; 65: 5278-83. (Pubitemid 40827339)
50. Mor G, Yue W, Santen RJ, et al. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 1998; 67: 403-11. (Pubitemid 29049413)
51. Ishikawa S, Egami H, Kurizaki T, Akagi J, Tamori Y, Yoshida N, Tan X, Hayashi N, Ogawa M. Identification of genes related to invasion and metastasis in pancreatic cancer by cDNA representational difference analysis. J Exp Clin Cancer Res 2003; 22: 299-306. (Pubitemid 36734189)
52. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995; 72: 818-23.
53. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol 2006; 18: 49-53. (Pubitemid 43049647)
54. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N. Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 2001; 28: 94-104. (Pubitemid 33065115)
55. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5: 1107-13. (Pubitemid 29233226)
56. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 2005; 4: 924-33. (Pubitemid 41598585)
57. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64: 275-90. (Pubitemid 28409233)
58. Park JS, Kim YS, Jee YK, Myong NH, Lee KY. Interleukin-8 production in tuberculous pleurisy: role of mesothelial cells stimulated by cytokine network involving tumour necrosis factor-alpha and interleukin-1 beta. Scand J Immunol 2003; 57: 463-9. (Pubitemid 36577906)
59. Sikora J, Dworacki G, Giersz R, Zeromski J. The role of monocytes/ macrophages in TCR-zeta chain downregulation and apop tosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents 2004; 18: 26-32. (Pubitemid 39193426)
60. Yanagawa E, Uchida A, Moore M, Micksche M. Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients. Cancer Immunol Immunother 1985; 19: 163-7. (Pubitemid 15013505)
61. España L, Fernández Y, Rubio N, Torregrosa A, Blanco J, Sierra A. Overexpression of Bcl-xL in human breast cancer cells enhances organselective lymph node metastasis. Breast Cancer Res Treat 2004; 87: 33-44.
62. Jung YJ, Kim JY, Park JH. TGF-beta1 inhibits Fas-mediated apoptosis by regulating surface Fas and cFLIPL expression in human leukaemia/lymphoma cells. Int J Mol Med 2004; 13: 99-104.
63. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix met-alloproteinase- 7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-81. (Pubitemid 32128617)
64. Kaczmarek M, Frydrychowicz M, Nowicka A, et al. Influence of pleural macrophages on proliferative activity and apoptosis regulating proteins of malignant cells. J Physiol Pharmacol 2008; 59 Suppl 6: 321-30.
65. Wilson HM, Walbaum D, Rees AJ. Macrophages and the kidney. Curr Opin Nephrol Hypertens 2004; 13: 285-90. (Pubitemid 38582301)
66. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1-9. (Pubitemid 351324128)
67. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-74. (Pubitemid 46211364)
68. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-33. (Pubitemid 39578752)
69. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005; 167: 627-35. (Pubitemid 41216349)
70. Schouwink H, Oppelaar H, Ruevekamp M, van der Valk M, Hart G, Rijken P, Baas P, Stewart FA. Oxygen depletion during and after mTH-PC- mediated photodynamic therapy in RIF1 and H-MESO1 tumors. Radiat Res 2003; 159: 190-8. (Pubitemid 36182397)
71. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, Lewis CE. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 2004; 103: 601-6. (Pubitemid 38140093)
72. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 2001; 50: 851-5.
73. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998; 64: 419-26. (Pubitemid 28455386)
74. Hennemann B, Scheibenbogen C, Schumichen C, Andreesen R. Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol 1995; 18: 19-27.
75. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65: 3437-46. (Pubitemid 40524630)
76. Cowen RL, Garside EJ, Fitzpatrick B, Papadopoulou MV, Williams KJ.. Gene therapy approaches to enhance bioreductive drug treatment. Br J Radiol 2008; 81 Spec 1: S45-56.
77. Carta L, Pastorino S, Melillo G, Bosco MC, Massazza S, Varesio L. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J Immunol 2001; 166: 5374-80. (Pubitemid 32374156)